Miopatías inflamatorias idiopáticas

  1. Movasat Hajkhan, A. 1
  2. Abassi Pérez, A. 1
  3. Bohórquez Heras, C. 1
  4. Pérez Gómez, A. 1
  1. 1 Servicio de Enfermedades del Sistema Inmune-Reumatología, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2021

Título do exemplar: Enfermedades del sistema inmune (V)

Serie: 13

Número: 32

Páxinas: 1799-1808

Tipo: Artigo

DOI: 10.1016/J.MED.2021.04.010 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of immune-mediated disorders, characterised by inflammation of the skeletal muscle. The 8 groups defined histologically and clinically are as follows: polymyositis (PM), adult dermatomyositis (DM), juvenile DM, amyopathic DM, inclusion-body myositis (IBM), immune-mediated necrotising myopathy (IMNM), myopathies associated with neoplasia and myopathies associated with other systemic autoimmune rheumatic conditions in the context of overlap syndromes. In addition to muscle weakness, there may be other extramuscular manifestations such as cutaneous, joint, lung, digestive and cardiac conditions. Up to 60% of the patients with IIM have antibodies that can be divided into 2 large groups: myositis-specific antibodies and myositis-associated antibodies that can be present overlapping with other systemic diseases. Muscle biopsy is essential for their diagnosis, given that the histopathological study defines the type of myositis. Treatment consists of high doses of glucocorticoids that, most of the time, requires immunosuppressive therapy as well.

Referencias bibliográficas

  • Acosta I, Matamala JM, Jara P, Pino F, Gallardo A, Verdugo R. Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo. Rev Med Chile. 2019;147:342-55.
  • Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(partI):344-7.
  • Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292 (partII):403-7.
  • Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Eng J Med. 1991;325:1487-98.
  • Svensson J, Arkema EV, Lundberg IE, Holmqvist M. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: A nationwide population based study. Rheumatology. 2017;56(5): 802-10.
  • Kaminsky A, Cáceres M, Charas V, Díaz M. Dermatomiositis. Med Cut Iber Lat Am. 2002;30:39-52.
  • Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia F. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci. 2008;15(12):1350-3.
  • Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J. The EuroMyositis registry: An international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77(1): 30-9.
  • Christopher Stine L, Basharat P. Statin Associated immune mediated myopathy: Biology and clinical implications. Curr Opin Lipidol. 2017;28: 186-92.
  • Riebeling Navarro C, Nava A. Patogenia de las miopatías inflamatorias idiopáticas. Reumatol Clin. 2009;5(S3):6-8.
  • Selva O’Callaghan A, Trallero Araguás E, Labrador Horrillo M, Grau Junyente JM. Miopatías inflamatorias. Medicine. 2017;12(29): 1679-89.
  • Needham M, Mastaglia FL. Sporadic inclusion body myositis: A continuing puzzle. Neuromuscul Disord. 2008;18:6-16.
  • Askanas V, Engel WK. Inclusion body some inhibition. Neurology. 2006;66:S39-48.
  • Oldfors A, Moslemi AR, Jonasson L, Ohlsson M, Kollberg G, Lindberg C. Mitochondrial abnormalities in inclusion body myositis. Neurology. 2006;66: S49-55.
  • Basharat P, Christopher Stine L. Immune mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17:72.
  • Mammen AL. Necrotizing myopathies: beyond statins. Curr Opin Rheu-matol. 2014;26:679-83.
  • Bottai M, Tiärnlund A, Santoni G, Weth V, Pilkington C, de Visser M. EULAR/ACR classification criteria for adult and juve-nile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;14;3(2):e000507.
  • Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M. International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classifica2017;76(12):1955-64.
  • Lundberg IE, De Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14:269-78.
  • Meyer A, Lannes B, Goetz J, Echaniz Laguna A, Lipsker D, Arnaud L. Inflammatory myopathies: A new landscape. J Bone Spine. 2018; 85(1):23-33.
  • Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638-56.
  • Kovacs S, Kovacs SC. Dermatomyositis. J Am Acad Dermatol. 1998;39: 899-920.
  • Callen JP, Jorizzo JL. Amyopathic dermatomyositis (dermatomyositis sine myositis). J Am Acad Dermatol. 1992;26:505-6.
  • Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med. 2019;40(3):561-72.
  • Nuño L, Joven B, Carreira P, Maldonado V, Larena C, Llorente I. Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: Descriptive Analysis. Reumatol Clin. 2017; 13(6):331-7.
  • El-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: Retrospective revison of 37 cases. J Am Acad Dermatol. 2002;46:560-5.
  • Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Med. 2013;92(1):25-41.
  • Felice K, North W. Inclusion body myositis in Connecticut: observations in 35 patients during an 8 year period. Medicine (Baltimore) 2001;80(5): 320-7.
  • Kassardjian C, Lennon V, Alfugham N, Mahler M, Milone M. Clinical features and treatment outcomes of necrotizing autoinmune myopathy. JAMA Neurol. 2015;72(9):996-1003.
  • Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. N Eng J Med. 1992;326:363-7.
  • Kaminsky A, Cáceres M, Charas V, Díaz M. Dermatomiositis. Med Cut Iber Lat Am. 2002;30:39-52.
  • Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275-85.
  • De Luca D, Staiger H, Carolina Baztán M, Enz P, Kowalczuk A, Galimberti R. Síndrome antisintetasa. Rev Asoc Colomb Dermatol. 2012;20: 4:381-4.
  • Macías I, Pérez JJ, García S. Síndrome antisintetasa. Semin Fund Esp Reumatol. 2007;8:28-33.
  • Fernández Piedra C, Navarro Martínez MV, Urkiza Bengo M. Síndrome antisintetasa, múltiples complicaciones. SEMERGEN. 2006;32(8):406-9.
  • Dalakas M, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362 (9388):971-82.
  • Bevilacqua J, Earle N. Miopatías inflamatorias. Rev Clin Con-des. 2018;29(6):611-21.
  • Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebophase trial. Arthritis Rheum. 2013;65(2): 314-24.
  • Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: A retrospective study of eight patients. Ann Rheum Dis. 2006;65(9):1233-6.
  • Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Studýnková JT. Abatacept in the treatment of adult dermatomyositis and polymyositis: A randomised, phase IIb treatment delayed start trial. Ann Rheum Dis. 2018;77(1):55-62
Fonte de datos: Dialnet